<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>13(12)</volume><submitter>Niu Z</submitter><pubmed_abstract>Breast cancer is the most common malignancy in women on a global scale. It can generally be divided into four main categories, of which estrogen receptor ER-positive breast cancer accounts for most breast cancer cases. RBCK1 protein is an E3 ubiquitin ligase containing the UBL, NZF, and RBR domains. It is well known to exhibit abnormal expression in breast tumors, making it a valuable diagnostic marker and drug target. Additionally, studies have confirmed that in breast cancer, about 25 to 40% of tumors appear as visible hypoxic regions, while in hypoxia, tumor cells can activate the hypoxia-inducing factor HIF1 pathway and widely activate the expression of downstream genes. Previous studies have confirmed that in the hypoxic environment of tumors, HIF1α promotes the remodeling of extracel</pubmed_abstract><journal>Cell death &amp; disease</journal><pagination>1023</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9726878</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>RBCK1 regulates the progression of ER-positive breast cancer through the HIF1α signaling.</pubmed_title><pmcid>PMC9726878</pmcid><pubmed_authors>Yang H</pubmed_authors><pubmed_authors>Li X</pubmed_authors><pubmed_authors>Zhuang T</pubmed_authors><pubmed_authors>Zhu J</pubmed_authors><pubmed_authors>Fan J</pubmed_authors><pubmed_authors>Niu Z</pubmed_authors><pubmed_authors>Chen F</pubmed_authors><pubmed_authors>Guo C</pubmed_authors><pubmed_authors>Wang H</pubmed_authors><pubmed_authors>Huang Q</pubmed_authors><pubmed_authors>Cao Q</pubmed_authors></additional><is_claimable>false</is_claimable><name>RBCK1 regulates the progression of ER-positive breast cancer through the HIF1α signaling.</name><description>Breast cancer is the most common malignancy in women on a global scale. It can generally be divided into four main categories, of which estrogen receptor ER-positive breast cancer accounts for most breast cancer cases. RBCK1 protein is an E3 ubiquitin ligase containing the UBL, NZF, and RBR domains. It is well known to exhibit abnormal expression in breast tumors, making it a valuable diagnostic marker and drug target. Additionally, studies have confirmed that in breast cancer, about 25 to 40% of tumors appear as visible hypoxic regions, while in hypoxia, tumor cells can activate the hypoxia-inducing factor HIF1 pathway and widely activate the expression of downstream genes. Previous studies have confirmed that in the hypoxic environment of tumors, HIF1α promotes the remodeling of extracel</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Dec</publication><modification>2026-07-14T15:56:34.046Z</modification><creation>2025-04-19T05:07:41.826Z</creation></dates><accession>S-EPMC9726878</accession><cross_references><pubmed>36473847</pubmed><doi>10.1038/s41419-022-05473-6</doi></cross_references></HashMap>